NCT05787496 - A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions

Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Chronic Myelomonocytic LeukemiaRelapsed or Refractory Myelodysplastic Syndrome

Interventions

DRUG

NC525

Monoclonal antibody specific for LAIR-1

Trial Locations (11)

Weill Cornell Medicine, New York

Roswell Park Cancer Institute, Buffalo

University of Miami, Miami

University Hospitals Cleveland Medical Center, Cleveland

Cleveland Clinic, Cleveland

Washington University School of Medicine in St. Louis, St Louis

MD Anderson Cancer Center, Houston

City of Hope, Duarte

Oregon Health & Science University, Portland

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston